Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $72.00

Oruka Therapeutics (NASDAQ:ORKA) had its price target boosted by analysts at Stifel Nicolaus from $47.00 to $72.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 81.57% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. Wedbush reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research report on Thursday, November 13th. They set a “buy” rating and a $45.00 target price on the stock. BTIG Research upped their target price on Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a report on Monday, January 12th. Finally, Guggenheim restated a “buy” rating and issued a $60.00 price target on shares of Oruka Therapeutics in a research report on Friday. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $56.44.

Oruka Therapeutics Stock Up 24.0%

ORKA stock traded up $7.67 during trading on Friday, hitting $39.66. The company had a trading volume of 398,567 shares, compared to its average volume of 420,671. The firm has a market cap of $1.92 billion, a PE ratio of -20.45 and a beta of -0.38. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $39.66. The firm has a 50-day moving average price of $32.68 and a 200-day moving average price of $27.32.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.16. Sell-side analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the sale, the insider directly owned 34,018 shares in the company, valued at $1,101,162.66. This represents a 17.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have sold 21,000 shares of company stock worth $663,530. Company insiders own 24.69% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Financial Enhancement Group LLC acquired a new position in shares of Oruka Therapeutics during the 3rd quarter valued at about $631,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of Oruka Therapeutics in the third quarter worth approximately $296,000. B Group Inc. grew its holdings in Oruka Therapeutics by 28.8% in the second quarter. B Group Inc. now owns 75,000 shares of the company’s stock valued at $841,000 after purchasing an additional 16,785 shares during the period. Geode Capital Management LLC increased its position in Oruka Therapeutics by 100.6% during the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after purchasing an additional 354,821 shares during the last quarter. Finally, Affinity Asset Advisors LLC increased its position in Oruka Therapeutics by 10.7% during the second quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock worth $6,765,000 after purchasing an additional 58,117 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.